Literature DB >> 8169981

p53 in non-small-cell lung cancer.

B Passlick, J R Izbicki, G Riethmüller, K Pantel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8169981     DOI： 10.1093/jnci/86.10.801

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  6 in total

Review 1.  Role of DMP1 and its future in lung cancer diagnostics.

Authors:  Takayuki Sugiyama; Donna P Frazier; Pankaj Taneja; Rachel L Morgan; Mark C Willingham; Kazushi Inoue
Journal:  Expert Rev Mol Diagn       Date:  2008-07       Impact factor: 5.225

Review 2.  New prognostic factors in resectable non-small cell lung cancer.

Authors:  E F Smit; H J Groen; T A Splinter; T Ebels; P E Postmus
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

Review 3.  Clinical implication of p53 mutation in lung cancer.

Authors:  Barbara G Campling; Wafik S El-Deiry
Journal:  Mol Biotechnol       Date:  2003-06       Impact factor: 2.695

4.  p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer.

Authors:  F J Vega; P Iniesta; T Caldés; A Sanchez; J A López; C de Juan; E Diaz-Rubio; A Torres; J L Balibrea; M Benito
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  p53 status predicts the efficacy of postoperative oral administration of tegafur for completely resected non-small cell lung cancer.

Authors:  F Tanaka; K Yanagihara; Y Ohtake; R Miyahara; Y Kawano; T Fukuse; S Hitomi; H Wada
Journal:  Jpn J Cancer Res       Date:  1999-04

6.  P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small-cell lung cancer.

Authors:  A Costa; R Silvestrini; C Mochen; C Lequaglie; P Boracchi; A Faranda; G Vessecchia; G Ravasi
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.